Vertex Pharmaceuticals, a cystic fibrosis powerhouse, is sprinting into new medical territories with big ambitions. The ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, ...

Vertex Pharmaceuticals Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

SillaJen researchers work on anti-cancer drugs (Courtesy of SillaJen) Qureator was co-founded by Jeon Noo-li, a mechanical engineering professor at Seoul National University and a leading expert in ...

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals is cranking up the charm on Wall Street with a whopping $4 billion share buyback plan, signaling ...

The stock's fall snapped a four-day winning streak.

With a market cap of $114.8 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company specializing in ...

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the first quarter ended March 31, 2025, ...

We believe Vertex is in strong financial health, given its robust cash flow generation and low debt. At the end of 2024, Vertex held about $11.2 billion in cash and equivalents.

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver disease franchise.